"I am extremely pleased to welcome two distinguished executives of the biotechnology industry to our Advisory Board," said Thomas Fischer, CEO EUCODIS Bioscience. "Dr. Rozzell as a successful founder and entrepreneur in the enzyme industry, and Dr. Bethke with entrepreneurial mindset and his track record in biotechnology manufacturing and operations, bring to EUCODIS Bioscience a wealth of hands-on experience and operational knowledge. Having these seasoned executives on our Advisory Board will be a tremendous asset to the Company as our customer base is growing rapidly. We will continue to expand our portfolio, and are aggressively addressing new business opportunities in the pharmaceutical, bioproducts, cosmetics, and other industries."
Dr. David Rozzell is President and CEO of Solidus Biosciences, a company providing research and analytical services to the pharmaceutical and cosmetics industry, enhancing their development productivity. Prior to joining Solidus as CEO, he was the Founder and CEO of enzyme developer BioCatalytics, which he grew to a leader in its field until the company was successfully sold to Codexis in 2007. Before founding BioCatalytics, Dr. Rozzell was President and COO of Exogene.
Dr. Ulf Bethke is Chief Operating Officer of Miltenyi Biotec, one of Germany's most successful biotechnology companies. Before joining Miltenyi Biotec in 1994, he was responsible for the development and production of therapeutic monoclonal antibodies at Biotest, a German pharmaceutical company.
Dr. Thomas Moser is Managing Partner at Pontis Capital, an Austrian venture capital company. He has 10 years of experience as an investment manager, overseeing the whole investment life-cycle, from deal acquisition through active management of portfolio companies to financing and implementation of the exit strategy.
Harald Schuerz is CEO of Wiener Wachstumsfond
|SOURCE EUCODIS Bioscience|
Copyright©2010 PR Newswire.
All rights reserved